We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$75.7M
Cap. Flow %
-9.66%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 55.74%
2 Industrials 4.06%
3 Utilities 2.54%
4 Technology 1.27%
5 Consumer Discretionary 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XLV icon
1
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
$66.2M 8.45%
10,000
+7,000
+233% +$512K
AGN
2
DELISTED
Allergan plc
AGN
$48.1M 6.14%
177,100
– –
SPY icon
3
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$47M 5.99%
+2,451
New +$497K
TEVA icon
4
Teva Pharmaceuticals
TEVA
$40.8B
$42.5M 5.42%
752,905
+575,605
+325% +$37.3M
XNTK icon
5
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
$37.4M 4.77%
6,000
+2,000
+50% +$102K
OEF icon
6
PUT
iShares S&P 100 ETF
OEF
$20.1B
$30.3M 3.87%
1,000
-13,615
-93% -$1.22M
ESLT icon
7
Elbit Systems
ESLT
$37.9B
$29.2M 3.72%
+100,618
New +$7.98M
BIIB icon
8
Biogen
BIIB
$30B
$24.8M 3.16%
85,000
+24,270
+40% +$8.01M
PFE icon
9
Pfizer
PFE
$143B
$18M 2.3%
605,010
-316,200
-34% -$10.1M
ABBV icon
10
AbbVie
ABBV
$443B
$17.8M 2.27%
327,000
-80,000
-20% -$5.21M
ORA icon
11
Ormat Technologies
ORA
$6B
$17.6M 2.24%
132,659
+52,567
+66% +$1.94M
SHPG
12
DELISTED
Shire pic
SHPG
$13.3M 1.69%
169,751
+35,000
+26% +$8.32M
BMRN icon
13
BioMarin Pharmaceuticals
BMRN
$11.6B
$13.2M 1.68%
125,000
+65,000
+108% +$8.68M
CELG
14
DELISTED
Celgene Corp
CELG
$13M 1.66%
120,000
-40,000
-25% -$4.96M
VTRS icon
15
CALL
Viatris
VTRS
$20.4B
$12.1M 1.54%
+3,000
New +$167K
GILD icon
16
Gilead Sciences
GILD
$162B
$11.8M 1.5%
120,000
-200,000
-63% -$22.2M
INCY icon
17
Incyte
INCY
$24.2B
$11M 1.41%
+100,000
New +$11.2M
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
$9.66M 1.23%
105,000
-15,000
-13% -$1.3M
BMY icon
19
Bristol-Myers Squibb
BMY
$133B
$8.88M 1.13%
150,000
+50,000
+50% +$3.17M
CEL
20
DELISTED
Cellcom Israel, Ltd.
CEL
$8.79M 1.12%
+357,452
New +$2.12M
PRGO icon
21
CALL
Perrigo
PRGO
$1.4B
$8.6M 1.1%
547
-453
-45% -$83.1K
VTRS icon
22
Viatris
VTRS
$20.4B
$8.05M 1.03%
200,000
+25,000
+14% +$1.39M
ACOR
23
DELISTED
Acorda Therapeutics
ACOR
$7.16M 0.91%
2,250
+1,000
+80% +$3.88M
AMGN icon
24
Amgen
AMGN
$208B
$6.94M 0.89%
50,200
-10,000
-17% -$1.58M
HZNP
25
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$6.94M 0.89%
+3,500
New +$111K
1
2 3 4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management withdrew a net $75.7M in Q3 2015, closing 36 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $22.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 51% a quarter earlier, followed by Industrials and Utilities.

Against the trend, Sphera Funds Management opened a new position in Incyte worth $11M.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceuticals in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.